<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04176588</url>
  </required_header>
  <id_info>
    <org_study_id>ES101002</org_study_id>
    <nct_id>NCT04176588</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Etrasimod for Induction and Maintenance Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Everstar Therapeutics Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Everstar Therapeutics Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether etrasimod is a safe and effective treatment
      for moderately to severely active ulcerative colitis.

      Condition or disease: Ulcerative Colitis Intervention/treatment: Drug: Etrasimod Drug:
      Placebo Phase: Phase 3
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)</measure>
    <time_frame>induction period week 12</time_frame>
    <description>Clinical remission per mMS(endoscopy, rectal bleeding, stool frequency), ranging from 0-9 (normal to severe)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Subjects With Clinical Remission Assessed by modified Mayo score(mMS)</measure>
    <time_frame>Maintenance period week 40</time_frame>
    <description>Clinical remission per mMS, ranging from 0-9 (normal to severe)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore</measure>
    <time_frame>induction period week 12</time_frame>
    <description>Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)</measure>
    <time_frame>induction period Week 12</time_frame>
    <description>Clinical response per mMS, ranging from 0 to 9 (normal to severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Achieving Endoscopic Improvement Assessed by endoscopic subscore</measure>
    <time_frame>Maintenance period Week 40</time_frame>
    <description>Endoscopic improvement per endoscopy subscore, ranging from 0 to 3 (normal to severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects with Clinical Response Assessed by modified Mayo score(mMS)</measure>
    <time_frame>Maintenance period Week 40</time_frame>
    <description>Clinical response per mMS, ranging from 0 to 9 (normal to severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects who achieve symptomatic response over time</measure>
    <time_frame>Open label treatment period up to 40 Weeks</time_frame>
    <description>Symptomatic response per paritial Mayo score(rectal bleeding, stool frequency), ranging from 0-6(normal to severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects who achieve Symptomatic Remission over time</measure>
    <time_frame>Open label treatment period up to 40 Weeks</time_frame>
    <description>Symptomatic remission per paritial Mayo score, ranging from 0-6(normal to severe)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">333</enrollment>
  <condition>Moderately to Severely Active Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Experimental: Etrasimod 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/tablet, administratered orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching tablet, administratered orally, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etrasimod 2mg (optional open-label extension period)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/tablet, administratered orally, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etrasimod</intervention_name>
    <description>Drug:Etrasimod Tablet other name:APD334</description>
    <arm_group_label>Etrasimod 2mg (optional open-label extension period)</arm_group_label>
    <arm_group_label>Experimental: Etrasimod 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drug:placebo Tablet</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A documented of diagnosis with UC at least 6 months prior to screening.

          2. Have active UC extending proximal to the rectum confirmed on endoscopy (â‰¥ 15 cm
             involved)

        Exclusion Criteria:

          1. Have severe extensive colitis

          2. Diagnosis of Crohn's disease or indeterminate colitis or the presence or history of a
             fistula consistent with Crohn's disease

          3. Diagnosis of microscopic colitis, ischemic colitis, infection colitis or colonic
             mucosal dysplasia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kaichun Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Fourth Military Medical University, PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qionghui Qiu, Asso. Project Director</last_name>
    <phone>86 21 5250 8621</phone>
    <email>qionghui.qiu@everestmedicines.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fourth Military Medical University, PLA</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaichun Wu Wu</last_name>
      <phone>029-84771502</phone>
      <email>kaicwu@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 22, 2019</study_first_submitted>
  <study_first_submitted_qc>November 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2019</study_first_posted>
  <last_update_submitted>November 25, 2019</last_update_submitted>
  <last_update_submitted_qc>November 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

